Sign in →

Test Code DHTES Dihydrotestosterone, Serum

Reporting Name

Dihydrotestosterone, S

Useful For

Monitoring patients receiving 5-alpha reductase inhibitor therapy or chemotherapy

 

Evaluating patients with possible 5-alpha reductase deficiency

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum


Specimen Required


Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Specimen Volume: 1 mL


Specimen Minimum Volume

0.6 mL

Testing Algorithm

See Steroid Pathways in Special Instructions.

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 7 days
  Frozen  90 days

Special Instructions

Reference Values

Males

Cord blood: ≤100 pg/mL

≤6 months: ≤1,200 pg/mL

Tanner Stages 

Mean

Age

Reference range (pg/mL)

Stage I (>6 months and prepubertal)

7.1 years

≤50

Stage II

12.1 years

≤200

Stage III

13.6 years

80-330

Stage IV

15.1 years

220-520

Stage V

18 years

240-650

>19 years: 112-955 pg/mL

 

Females

Cord blood: ≤50 pg/mL

≤6 months: ≤1,200 pg/mL

Tanner Stages 

Mean

Age

Reference range (pg/mL)

Stage I (>6 months and prepubertal)

7.1 years

≤50

Stage II

10.5 years

≤300

Stage III

11.6 years

≤300

Stage IV

12.3 years

≤300

Stage V

14.5 years

≤300

20-55 years: ≤300 pg/mL

>55 years: ≤128 pg/mL

 

1. Pang S, Levine LS, Chow D, et al: Dihydrotestosterone and its relationship to testosterone in infancy and childhood. J Clin Endocrinol Metab 1979;48:821-826

2. Stanczyk FZ: Diagnosis of hyperandrogenism: biochemical criteria. Best Pract Res Clin Endocrinol Metab 2006;20(2):177-191

Day(s) and Time(s) Performed

Monday, Thursday

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

82642

G0480 (if appropriate)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
DHTS Dihydrotestosterone, S 1848-1

 

Result ID Test Result Name Result LOINC Value
81479 Dihydrotestosterone, S 1848-1

Clinical Reference

1. Bartsch G, Rittmaster RS, Klocker H: Dihydrotestosterone and the concept of 5 alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002;19(6):413-425

2. Trueb RM: Molecular mechanisms of androgenetic alopecia. Exp Gerontol 2002;37(8-9):981-990

3. Singh SM, Gauthier S, Labrie F: Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem 2000;7(2):211-247

4. Rhodes L, Harper J, Uno H, et al: The effects of finasteride (Proscar) on hair growth, hair cycle stage, and serum testosterone and dihydrotestosterone in adult male and female stumptail macaques (Macaca arctoides). J Clin Endocrinol Metab 1994;79:991-996

5. Gustafsson O, Norming U, Gustafsson S, et al: Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population. Br J Urol 1996;77:433-440

6. van der Veen A, van Faassen M, de Jong WHA, et al: Development and validation of a LC-MS/MS method for the establishment of reference intervals and biological variation for five plasma steroid hormones. Clin Biochem. 2019 Jun;68:15-23. doi: 10.1016/j.clinbiochem.2019.03.013

Method Description

Deuterated stable isotope of dihydrotestosterone (DHT) is added to a 0.5-mL serum sample as internal standard. The DHT and internal standard are extracted from the sample by solid phase extraction. This is followed by conventional liquid chromatography on a multiplexed LC System and analysis on a tandem mass spectrometer equipped with an electrospray ionizer.(Lagerstedt SA, O'Kane DJ, Singh RJ: Measurement of plasma free metanephrine and normetanephrine by liquid chromatography-tandem mass spectrometry for diagnosis of pheochromocytoma. Clin Chem 2004;50[3]:603-611)

Analytic Time

2 days

Reject Due To

Gross hemolysis OK
Gross lipemia OK
Gross icterus OK

Method Name

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

Portions of this test are covered by patents held by Quest Diagnostics